Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Trial Profile

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OP-801 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Ashvattha Therapeutics

Most Recent Events

  • 02 May 2025 Planned End Date changed from 1 Mar 2025 to 1 May 2026.
  • 02 May 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
  • 13 Jan 2025 According to an Ashvattha Therapeutics media release, the company has announced additional financing as an extension of its Series B of up to $50 million led by Tribe Capital with existing investors led by Natural Capital. The funding will enable company to complete this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top